The combination of ribociclib and fulvestrant yielded an improvement in progression-free survival in postmenopausal women with advanced breast cancer, according to the MONALEESA-3 trial.
More From BioPortfolio on "Ribociclib Plus Fulvestrant Offers Improved PFS in Advanced Breast Cancer"